Skip to main content
NIH Clinical Center
  Home | Contact Us | Site Map | Search
About the Clinical Center
For Researchers and Physicians
Participate in Clinical Studies

Back to: Clinical Center Home Page > About the Clinical Center > Senior Staff
 
Senior Staff

Deborah Merke, MD, MS
Chief
Pediatric Consult Service

Academic Degrees
B.S., M.D., University of Minnesota
M.D., State University of New York at Buffalo

Email: dmerke@nih.gov

Phone: 301-496-0718

Portrait of Deborah Merke

Biosketch

Dr. Deborah Merke graduated cum laude from University of Massachusetts, received a master of science degree in biostatistics from Columbia University and earned her medical degree from State University of New York at Buffalo. During medical school, she was elected to the Alpha Omega Alpha (medical honor) Society. She completed her pediatric residency at the Children’s Hospital of Philadelphia and a fellowship in pediatric endocrinology at the National Institute of Child Health and Human Development. As a fellow, she received an NIH Clinical Research Loan Repayment and Scholarship Award and an NIH Fellows Award for Research Excellence. After completion of her fellowship, Dr. Merke remained at NICHD studying congenital adrenal hyperplasia, a rare disease of the adrenal gland. Dr. Merke is now considered a world expert in CAH.

In 1999, Dr. Merke was appointed chief of Pediatric Services for the NIH Clinical Center. In this position, she oversees the care of pediatric patients at the CC, heads the Pediatric Consult Service, and chairs the Pediatric Care Committee?the organizational committee responsible for overseeing clinical policies and guidelines for managing pediatric patient care. She also maintains a joint appointment as an NICHD clinical investigator and continues to oversee clinical research studies of CAH.

Dr. Merke has made significant contributions to the study of CAH?including the novel finding of adrenaline deficiency in patients with CAH, the discovery that patients with CAH have smaller-than-normal amygdalas (the part of the brain that regulates emotion) and identification of problems with hydrocortisone suspension; this is a common medication used by patients with CAH, and Dr. Merke’s studies led to a product recall. She currently is principal investigator of a clinical trial testing a new treatment regimen for children with CAH and a natural history study of CAH that aims to broaden our understanding of the disease process. Dr. Merke leads an effort to expand our understanding of the pathophysiology and clinical manifestations of CAH through collaborative studies with the National Institute of Mental Health and the National Institute of Aging. She recently received a 2005 and 2006 grant from the Congenital Adrenal Hyperplasia Research, Education and Support Foundation.

She has published widely in New England Journal of Medicine, Lancet, Journal of the American Medical Association, and Journal of Clinical Endocrinology and Metabolism, and in other medical journals.

Honors and Awards

Congenital Adrenal Hyperplasia Research, Education and Support Foundation, Inc. grant in support of research in the area of congenital adrenal hyperplasia ($62,500), 2005 and 2006; NIH Fellows Award for Research Excellence, 1997; NIH Clinical Research Loan Repayment and Scholarship Award, 1996; Dr. Louis Sklarow Memorial Award for outstanding graduate in medicine, SUNY at Buffalo, 1991; senior honors thesis: Predicting Mortality and Five Year Neurodevelopmental Morbidity in Extremely Premature Infants, 1991; Alpha Omega Alpha Society, 1990; Dean’s Commendation for Honors Achievement, 1989 & 1990; Dean’s Commendation for research presentation at SUNY at Buffalo, Medical School Student Research Forum, among top ten. 1988; Cum Laude Graduate, University of Massachusetts. 1982; Alumni Scholarship Award for academic excellence, University of Massachusetts, 1981.

Selected Publications

BOOKS AND BOOK CHAPTERS

Charmandari E, Chrousos GP, Merke DP. Classic congenital adrenal hyperplasia. In: Adrenal Glands: diagnostic aspects and surgical therapy, Chapter 10, pp 101-114. Linos DA, VanHeerden JA, eds., Springer-Verlag, Germany 2005.

Merke DP, Cutler GB. New ideas for medical treatment of Congenital Adrenal Hyperplasia. Endocrinology and Metabolism Clinics of North America 30:121-135, 2001.

Merke DP, Camacho CA. Novel Basic and Clinical Aspects of Congenital Adrenal Hyperplasia. Reviews in Endocrine & Metabolic Disorders 2:289-296, 2001.

Miller RW, Merke DP. Radiation injury. In: Nelson WE et al, eds., Nelson Textbook of Pediatrics, 15th ed. W.B. Saunders, Philadelphia, 2002-4, 1996.

JOURNAL ARTICLES

Merke DP, Cutler GB. New approaches to the treatment of congenital adrenal hyperplasia. JAMA 277:1073-6, 1997.

Merke DP, Bornstein SR, Braddock D, Chrousos GP. Adrenal lymphocytic infiltration and adrenocortical tumors in a patient with 21-hydroxylase deficiency. N Engl J Med 340:1121-1122, 1999.

Merke DP, Tajima T, Baron J, Cutler GB. Hypogonadotropic hypogonadism in a female caused by an X-linked recessive mutation in the DAX-1 gene. N Engl J Med 340:1248-1252, 1999.

Avila NA, Shawker TS, Jones JV, Cutler GB, Merke DP. Testicular adrenal rest tissue in congenital adrenal hyperplasia: Serial ultrasound and clinical findings. AJR 172:1235-1238, 1999.

Merke DP, Keil M, Jones JV, Fields J, Hill S, Cutler GB. Flutamide, testolactone, and reduced hydrocortisone dose maintains normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 85:1114-1120, 2000.

Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil M, Rogol AD, Van Wyk JJ, Bornstein SR. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343:1362-1368, 2000.

Merke DP, Cho D, Calis KA, Keil MF, Chrousos GP. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 86:441-445, 2001.

Merke DP, Bornstein SR, Avila NA, Chrousos GP. NIH Conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Annals of Internal Medicine 136(4):320-334, 2002.

Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: Potential clinical implications. J Clin Endocrinol Metab 87:2114-2120, 2002.

Charmandari E, Eisenhofer G, Mehlinger SL, Carlson A, Wesley R, Keil MF, Chrousos GP, New MI, Merke DP. Adrenomedullary function may predict phenotype and genotype in classic 21-hydroxylase deficiency. J Clin Endocrinol Metab, 87:3031-3037, 2002.

Merke DP, Fields JD, Keil MF, Vaituzis AC, Chrousos GP, Giedd JN. Children with classic congenital adrenal hyperplasia have decreased amygdala volume: Potential prenatal and postnatal hormonal effects. J Clin Endocrinol Metab, 88:1760-1765, 2003.

Weise M, Mehlinger SL, Drinkard B, Rawson E, Charmandari E, Hiroi M, Eisenhofer G, Yanovski JA, Chrousos GP, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glucose elevation in response to high intensity exercise. J Clin Endocrinol Metab, 89:591-597, 2004.

Merke DP and Bornstein SR. Seminar: Congenital Adrenal Hyperplasia. The Lancet, 365:2125-2136, 2005.

This page last reviewed on 06/27/08



National Institutes
of Health
  Department of Health
and Human Services
 
NIH Clinical Center National Institutes of Health